Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy |
Oct 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
Oct 2020 |
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? |
Oct 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? |
Oct 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp |
Sep 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
Sep 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes |
Sep 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
Is blood transfusion safe during the COVID-19 pandemic? |
Sep 2020 |
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
Sep 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
Sep 2020 |
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |